Active Proliferative Lupus Nephritis: When Initial Treatment Fails to Meet Proteinuria Targets

This protocol applies to patients with active proliferative lupus nephritis — specifically those without reduced glomerular filtration rate, cellular crescents, fibrinoid necrosis, or severe interstitial inflammation — whose renal response to initial induction therapy has been inadequate, or who experience a disease flare.

Clinical Scenario

Active proliferative lupus nephritis without reduced glomerular filtration rate, without cellular crescents, without fibrinoid necrosis, and without severe interstitial inflammation. Defined renal response targets from the first treatment line have not been achieved.

Previous Treatment Line — Targets Not Met

Initial induction therapy for active proliferative lupus nephritis — including agents such as hydroxychloroquine, glucocorticoids, mycophenolate, cyclophosphamide, and, where indicated, combination approaches with belimumab or calcineurin inhibitors — aimed to reach:

Proteinuria reduction ≥25% at 3 months
Proteinuria reduction ≥50% at 6 months
Proteinuria below 500–700 mg/day at 12 months
Glomerular filtration rate within 10% from baseline

Failure to reach these targets — or a subsequent flare — triggers the next structured step.

Next-Step Approach (Partial)

For patients who did not initially receive combination therapy, add-on targeted therapy is considered — the complete agent selection and criteria are detailed in the full protocol.

Treatment Goals

Reduction in proteinuria ≥50% at 6 months
Proteinuria below 500–700 mg/day at 12 months
Glomerular filtration rate within 10% from baseline

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ard-2023-224762

Patients with active proliferative lupus nephritis should receive low-dose (EuroLupus) intravenous cyclophosphamide (1a/A) or mycophenolate (1a/A) and glucocorticoids (pulses of intravenous methylprednisolone followed by lower oral doses); combination therapy with belimumab (either with cyclophosphamide or mycophenolate (1b/A)) or calcineurin inhibitors (especially voclosporin or tacrolimus, combined with mycophenolate, 1b/A) should be considered.

If a combination therapy is not opted for in patients with treatment-naive LN, add-on treatment with belimumab or voclosporin should be considered in patients with inadequate response by 3–6 months, or those who flare.

Following the choice of initial treatment, renal response should be monitored according to the 2019 EULAR/ERA-EDTA targets (reduction in proteinuria ≥25% and 50% at 3 and 6 months, respectively, and below 500–700 mg/day at 12 months, all with GFR within 10% from baseline).

View source ↗